Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis-Reference-Cited by-同舟云学术

Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis

Published:2015-06-30 Issue:1 Volume:17 Page:62-67
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Casado JL¹,Mena A²,Bañón S¹,Castro A²,Quereda C¹,Moreno A¹,Pedreira J²,Moreno S¹

Affiliation:

1. Department of Infectious Diseases; Ramon y Cajal Hospital; Madrid Spain

2. Department of Internal Medicine; INIBIC-Complexo Universitario Hospitalario; A Coruña Spain

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Reference21 articles.

1. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results;Gazzard;AIDS,2011

2. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials;Katlama;Antivir Ther,2010

3. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management;Núñez;J Hepatol,2006

4. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors;Rivero;J Antimicrob Chemother,2007

5. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection;Aranzabal;Clin Infect Dis,2005

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current insights and molecular docking studies of HIV‐1 reverse transcriptase inhibitors;Chemical Biology & Drug Design;2023-10-10

2. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting;Viruses;2023-07-23

3. Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens;BMC Infectious Diseases;2023-04-14

4. HIV and liver disease;Aids Reviews;2022-06-28

5. Hepatotoxicity of contemporary antiretroviral drugs;Current Opinion in HIV and AIDS;2021-09-20